Malaria epidemics represent one of the life-threatening diseases to low-income lying countries which subsequently affect the economic and social condition of mankind. In continuation in the development of a novel series of 1,2,4-trioxanes 13a1-c1, 13a2-c2, and 13a3-c3 have been prepared and further converted into their hemisuccinate derivatives 14a1-c1, 14a2-c2, and 14a3-c3 respectively. All these new compounds were evaluated for their antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in mice by both oral and intramuscular (im) routes. Hydroxy-functionalized trioxane 13a1 showed 80% protection and its hemisuccinate derivative 14a1 showed 100% protection at a dose of 48 mg/kg × 4 days by both routes, which is twice active than artemisinin by oral route.

疟疾流行是对低收入国家构成威胁生命的疾病之一，随后会影响人类的经济和社会状况。在一系列新的1,2,4-三氧杂环己烷的发展继续13A1-C1，13A2-C2，和13A3-C3已经制备并进一步转化成其半琥珀酸酯衍生物14A1-C1，14A2-C2，和14a3- c3分别。通过口服和肌肉注射 (im) 途径，评估了所有这些新化合物对小鼠体内耐多药约氏疟原虫的抗疟活性。羟基官能化的三恶烷13a1显示 80% 的保护作用，其半琥珀酸酯衍生物14a1在 48 mg/kg × 4 天的剂量下通过两种途径显示出 100% 的保护作用，其活性是口服途径青蒿素的两倍。